# TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/TGTX/tg-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-healthcare-conference
Ticker: TGTX
Company: TG Therapeutics
Source: TG Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.tgtherapeutics.com
## Summary

Fireside chat scheduled for Tuesday, June 9, 2026, at 2:00 PM ET NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 47 th Annual Healthcare

## Article Body
Fireside chat scheduled for Tuesday, June 9, 2026, at 2:00 PM ET NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 47 th Annual Healthcare
## Recent Company News
- 2026-07-06 11:30 EST — [TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia](https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-initiation-of-phase-2-trial-evaluating-briumvi-in-pati-4f9159d1) — Source: TG Therapeutics
- 2026-06-25 13:46 EST — [TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial](https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-positive-topline-phase-1-data-for-subcutaneous-briumvi-in-patients-with-myasthenia-gravis-and-initiation-of-potential-registration-directed-randomized-phase-2-trial) — Source: TG Therapeutics
- 2026-06-25 13:46 EST — [TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)](https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-positive-results-from-phase-1-trial-evaluating-subcutaneous-briumvir-ublituximab-xiiy) — Source: TG Therapeutics
- 2026-06-25 13:46 EST — [TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference](https://biopharmsignal.com/news/TGTX/tg-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-healthcare-conference) — Source: TG Therapeutics
- 2026-06-25 13:46 EST — [TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology](https://biopharmsignal.com/news/TGTX/tg-therapeutics-announces-publication-of-post-hoc-data-from-the-phase-3-ultimate-i-and-ii-trials-in-treatment-naive-patients-with-relapsing-forms-of-ms-published-in-frontiers-in-immunology) — Source: TG Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)